A cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia

NeuroReport

Volumn 10, Issue 7, 1999, Pages 1461-1465

  Wakita, Hideaki ^a   Tomimoto, Hidekazu ^a   Akiguchi, Ichiro ^a   Lin, Jin Xi ^a   Miyamoto, Katsuichi ^a   Oka, Nobuyuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 2 inhibitor; Ischemic cerebrovascular disease; Major histocompatibility complex antigen; Nimesulide; Rat; White matter rarefaction

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; NIMESULIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PERFUSION; CHRONIC DISEASE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; IMMUNOREACTIVITY; MACROGLIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; WHITE MATTER;

EID: 0033553313     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199905140-00013     Document Type: Article

References (25)

1. 1. Smith WL and DeWitt DL. Semin Nephrol 15, 179-194 (1995).
2. 2. Smith WL, Garavito RM and DeWitt DL. J Biol Chem 271, 33157-33160 (1996).
3. 3. Nogawa S, Zhang F, Ross ME and Iadecola C. J Neurosci 17, 2746-2755 (1997).
4. 4. Iadecola C and Ross ME. Ann New York Acad Sci 835, 203-217 (1997).
5. 5. Pantoni L and Garcia JH. Stroke 28, 652-659 (1997).
6. 6. Tsuchiya M, Sako K, Yura S and Yonemasu Y. Exp Brain Res 89, 87-92 (1992).
7. 7. Otori T, Katsumata T, Kashiwagi F et al. Cerebrovasc Dis 6 (Suppl.), 71 (1996).
8. 8. Tomimoto H, Akiguchi I, Wakita H and Kimura J. Brain Nerve 49, 639-644 (1997).
9. 9. Ohta H, Nishikawa H, Kimura H et al. Neuroscience 79, 1039-1050 (1997).
10. 10. Wakita H, Tomimoto H, Akigucni I and Kimura J. Acta Neurophatol (Berl) 87, 484-492 (1994).
11. 11. Wakita H, Tomimoto H, Akiguchi I and Kimura J. Stroke 26, 1415-1422 (1995).
12. 12. Wakita H, Tomimoto H, Akiguchi I and Kimura J. Brain Res 792, 105-113 (1998).
13. 13. Tomimoto H, Akiguchi I, Akiyama H et al. Am J Pathol 143, 579-586 (1993).
14. 14. Akiguchi I, Tomimoto H, Suenaga T et al. Stroke 28, 1423-1429 (1997).
15. 15. Barnett J, Chow J, Ives D et al. Biochem Biophys Acta 1209, 130-139 (1994).
16. 16. Ward A and Brogden RN. Drugs 36, 732-753 (1988).
17. 17. Busto R, Dietrich WD, Globus MYT and Ginsberg MD. Stroke 20, 1113-1114 (1989).
18. 16. Warrington SJ, Ravic M and Dawnay A. Drugs 46 (Suppl. 1), 263-269 (1993).
19. 19. Seibert K, Masferrer J, Zhang Y et al. Agents Actions Suppl 46, 41-50 (1995).
20. 20. Kontos HA, Wei EP, Povlishock JT et al. Science 209, 1242-1245 (1980).
21. 21. Hall ED, Andrus PK, Althaus JS and VonVoigtlander PF. J Neurosci Res 34, 107-112 (1993).
22. 22. Sairanen T, Ristimákl A, Karjalainen-Lindsberg ML et al. Ann Neurol 43, 738-747 (1998).
23. 23. Théry C, Chamak B and Mallat M. Eur J Neurosci 3, 1155-1164 (1991).
24. 24. Lees GJ. J Neurol Sci 114, 119-122 (1993).
25. 25. Guastadlsegni C, Minghetti L, Nicolini A et al. FEBS Lett 413, 314-318 (1997).